人民财讯9月18日电，精华制药（002349）9月18日晚间公告，近日，公司收到江苏省药品监督管理局核 发的医用海藻酸钠创面敷料《中华人民共和国医疗器械注册证》。医用海藻酸钠创面敷料开发初衷为辅 助公司核心产品季德胜蛇药片外用，以期为片剂外用提供更便利的使用方式与更好的体验。 ...

格隆汇9月18日丨精华制药(002349.SZ)公布，收到江苏省药品监督管理局核发的医用海藻酸钠创面敷料 《中华人民共和国医疗器械注册证》，医用海藻酸钠创面敷料开发初衷为辅助公司核心产品季德胜蛇药 片外用，以期为片剂外用提供更便利的使用方式与更好的体验。该产品由海藻酸钠、甘油、1，3-丁二 醇、卡波姆等成分组成，所含组分无药理学作用、不可被人体吸收，以无菌状态提供，经辐照灭菌且为 一次性使用。能为创面营造适宜的湿润环境，同时具备良好的生物相容性、抗菌性等特点，适用于浅表 性创面及周围皮肤的护理。在辅助季德胜蛇药片外用时，主要通过为片剂外用提供便利的使用载体与适 宜环境，便于临床及患者更便捷地使用季德胜蛇药片开展外用护理。 ...

Core Viewpoint - The company demonstrates resilience and growth potential in a complex industry environment, with steady revenue growth, significant cash flow improvement, and enhanced competitiveness of core products, alongside advancing internationalization and R&D innovation [1]. Financial Performance - For the first half of 2025, the company achieved revenue of 731 million yuan, a year-on-year increase of 1.54%; net profit attributable to shareholders was 131 million yuan, with a net profit of 127 million yuan after excluding non-recurring gains and losses, indicating solid profitability in core operations [2]. - The net cash flow from operating activities surged by 31.87% to 128 million yuan, reflecting improved operational quality and enhanced capital management efficiency [2]. Core Product Strength - Sales revenue from traditional Chinese medicine preparations grew by 12.45% year-on-year to 287 million yuan, serving as a key support for performance [3]. - Key products such as "Wang's Baochi Pill," "Jide Sheng Snake Medicine Tablets," and "Zheng Chai Hu Drink Granules" continue to gain clinical and market recognition due to their unique efficacy and strong brand heritage [3]. - "Wang's Baochi Pill" was included in the "International Clinical Practice Guidelines for Functional Dyspepsia in Traditional Chinese Medicine (2025 Edition)," enhancing its international influence [3]. International Expansion - The company actively expanded its overseas market, achieving self-operated export sales of 11.3 million USD, a year-on-year increase of 16% [4]. - Several raw material drug varieties have received FDA and CEP certifications, gaining international quality recognition [4]. R&D and Capacity Development - The company places high importance on R&D investment, collaborating with universities on various pharmacological and clinical research projects [5]. - The approval of new indications for "Diphenhydramine Hydrochloride Tablets" by the National Medical Products Administration further enriches the product line [5]. - Projects for traditional Chinese medicine preparation production bases, GMP certification upgrades, and energy-saving renovations are progressing steadily, laying the foundation for future capacity release and quality upgrades [5]. Cost Reduction and Efficiency Improvement - Through process optimization, intelligent equipment upgrades, and procurement cost control, the company achieved cost reductions exceeding 5 million yuan in the first half of the year [6]. - A successful stock incentive plan was implemented in May, granting 15.494 million restricted shares to 105 core employees, effectively motivating the team for long-term development [6]. Social Responsibility - The company continues to promote the construction of GAP bases for Chinese medicinal materials in Gansu Longxi, adopting a "leading enterprise + base + cooperative" model to boost local farmers' income [7]. - During the reporting period, the company procured local medicinal materials worth 30.946 million yuan, creating over 70 jobs, showcasing the responsibility and commitment of state-owned enterprises [7].

Core Insights - The report highlights the positive performance of the pharmaceutical index, with five out of six sub-industries recording positive returns this week [2] - The approval of the traditional Chinese medicine "Loquat Lung Clearing Granules," developed by Xiamen University and Shenwei Pharmaceutical, marks a significant achievement in the modernization of traditional medicine, showcasing the integration of ancient wisdom with modern technology [3][8] - The Chinese traditional medicine industry is entering a new phase of high-quality development, supported by government policies and technological innovations, with the market size expected to exceed 480 billion yuan by 2024 [9][10] Industry Performance Review - The pharmaceutical sector, particularly the chemical pharmaceuticals and traditional Chinese medicine sub-industries, showed strong performance with increases of 5.01% and 3.12% respectively [14] - The valuation levels for the chemical pharmaceuticals and biological products were the highest at 92.95 times and 74.63 times respectively, while traditional Chinese medicine had a valuation of 34.05 times [14] Industry Trends and Developments - The report discusses the implementation of the "Strong Foundation Project" by the National Development and Reform Commission, aimed at enhancing grassroots healthcare services and promoting the integration of traditional Chinese medicine into the healthcare system [21] - The introduction of policies in Henan Province to include suitable traditional Chinese medicine techniques in medical insurance coverage is expected to alleviate the economic burden on patients and promote the use of traditional medicine in chronic disease treatment [26][30]